Recombinant Non-Glycosylated Proteins Biosimilars Market
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Insulin
1.2.3 rHGH
1.2.4 Interferon
1.3 Market by Application
1.3.1 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Oncology
1.3.3 Chronic Diseases
1.3.4 Autoimmune Diseases
1.3.5 Blood Disorders
1.3.6 Growth Hormone Deficiency
1.3.7 Infectious Diseases
1.3.8 Other Diseases
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Perspective (2017-2028)
2.2 Recombinant Non-Glycosylated Proteins Biosimilars Growth Trends by Region
2.2.1 Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Recombinant Non-Glycosylated Proteins Biosimilars Historic Market Size by Region (2017-2022)
2.2.3 Recombinant Non-Glycosylated Proteins Biosimilars Forecasted Market Size by Region (2023-2028)
2.3 Recombinant Non-Glycosylated Proteins Biosimilars Market Dynamics
2.3.1 Recombinant Non-Glycosylated Proteins Biosimilars Industry Trends
2.3.2 Recombinant Non-Glycosylated Proteins Biosimilars Market Drivers
2.3.3 Recombinant Non-Glycosylated Proteins Biosimilars Market Challenges
2.3.4 Recombinant Non-Glycosylated Proteins Biosimilars Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Recombinant Non-Glycosylated Proteins Biosimilars Players by Revenue
3.1.1 Global Top Recombinant Non-Glycosylated Proteins Biosimilars Players by Revenue (2017-2022)
3.1.2 Global Recombinant Non-Glycosylated Proteins Biosimilars Revenue Market Share by Players (2017-2022)
3.2 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Recombinant Non-Glycosylated Proteins Biosimilars Revenue
3.4 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Concentration Ratio
3.4.1 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recombinant Non-Glycosylated Proteins Biosimilars Revenue in 2021
3.5 Recombinant Non-Glycosylated Proteins Biosimilars Key Players Head office and Area Served
3.6 Key Players Recombinant Non-Glycosylated Proteins Biosimilars Product Solution and Service
3.7 Date of Enter into Recombinant Non-Glycosylated Proteins Biosimilars Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Recombinant Non-Glycosylated Proteins Biosimilars Breakdown Data by Type
4.1 Global Recombinant Non-Glycosylated Proteins Biosimilars Historic Market Size by Type (2017-2022)
4.2 Global Recombinant Non-Glycosylated Proteins Biosimilars Forecasted Market Size by Type (2023-2028)
5 Recombinant Non-Glycosylated Proteins Biosimilars Breakdown Data by Application
5.1 Global Recombinant Non-Glycosylated Proteins Biosimilars Historic Market Size by Application (2017-2022)
5.2 Global Recombinant Non-Glycosylated Proteins Biosimilars Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size (2017-2028)
6.2 North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2017-2022)
6.3 North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size (2017-2028)
7.2 Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2017-2022)
7.3 Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size (2017-2028)
8.2 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2017-2022)
8.3 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size (2017-2028)
9.2 Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2017-2022)
9.3 Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size (2017-2028)
10.2 Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2017-2022)
10.3 Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Sandoz
11.1.1 Sandoz Company Detail
11.1.2 Sandoz Business Overview
11.1.3 Sandoz Recombinant Non-Glycosylated Proteins Biosimilars Introduction
11.1.4 Sandoz Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022)
11.1.5 Sandoz Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Recombinant Non-Glycosylated Proteins Biosimilars Introduction
11.2.4 Pfizer Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022)
11.2.5 Pfizer Recent Development
11.3 Teva Pahrmaceutical
11.3.1 Teva Pahrmaceutical Company Detail
11.3.2 Teva Pahrmaceutical Business Overview
11.3.3 Teva Pahrmaceutical Recombinant Non-Glycosylated Proteins Biosimilars Introduction
11.3.4 Teva Pahrmaceutical Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022)
11.3.5 Teva Pahrmaceutical Recent Development
11.4 Celltrion
11.4.1 Celltrion Company Detail
11.4.2 Celltrion Business Overview
11.4.3 Celltrion Recombinant Non-Glycosylated Proteins Biosimilars Introduction
11.4.4 Celltrion Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022)
11.4.5 Celltrion Recent Development
11.5 Biocon
11.5.1 Biocon Company Detail
11.5.2 Biocon Business Overview
11.5.3 Biocon Recombinant Non-Glycosylated Proteins Biosimilars Introduction
11.5.4 Biocon Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022)
11.5.5 Biocon Recent Development
11.6 Amgen
11.6.1 Amgen Company Detail
11.6.2 Amgen Business Overview
11.6.3 Amgen Recombinant Non-Glycosylated Proteins Biosimilars Introduction
11.6.4 Amgen Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022)
11.6.5 Amgen Recent Development
11.7 Samsung Biologics
11.7.1 Samsung Biologics Company Detail
11.7.2 Samsung Biologics Business Overview
11.7.3 Samsung Biologics Recombinant Non-Glycosylated Proteins Biosimilars Introduction
11.7.4 Samsung Biologics Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022)
11.7.5 Samsung Biologics Recent Development
11.8 Mylan
11.8.1 Mylan Company Detail
11.8.2 Mylan Business Overview
11.8.3 Mylan Recombinant Non-Glycosylated Proteins Biosimilars Introduction
11.8.4 Mylan Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022)
11.8.5 Mylan Recent Development
11.9 Dr. Reddy's Laboratories
11.9.1 Dr. Reddy's Laboratories Company Detail
11.9.2 Dr. Reddy's Laboratories Business Overview
11.9.3 Dr. Reddy's Laboratories Recombinant Non-Glycosylated Proteins Biosimilars Introduction
11.9.4 Dr. Reddy's Laboratories Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022)
11.9.5 Dr. Reddy's Laboratories Recent Development
11.10 Stada Arzneimittel AG
11.10.1 Stada Arzneimittel AG Company Detail
11.10.2 Stada Arzneimittel AG Business Overview
11.10.3 Stada Arzneimittel AG Recombinant Non-Glycosylated Proteins Biosimilars Introduction
11.10.4 Stada Arzneimittel AG Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022)
11.10.5 Stada Arzneimittel AG Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Insulin
Table 3. Key Players of rHGH
Table 4. Key Players of Interferon
Table 5. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Region (2017-2022) & (US$ Million)
Table 8. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Region (2017-2022)
Table 9. Global Recombinant Non-Glycosylated Proteins Biosimilars Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 10. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Region (2023-2028)
Table 11. Recombinant Non-Glycosylated Proteins Biosimilars Market Trends
Table 12. Recombinant Non-Glycosylated Proteins Biosimilars Market Drivers
Table 13. Recombinant Non-Glycosylated Proteins Biosimilars Market Challenges
Table 14. Recombinant Non-Glycosylated Proteins Biosimilars Market Restraints
Table 15. Global Recombinant Non-Glycosylated Proteins Biosimilars Revenue by Players (2017-2022) & (US$ Million)
Table 16. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Players (2017-2022)
Table 17. Global Top Recombinant Non-Glycosylated Proteins Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Non-Glycosylated Proteins Biosimilars as of 2021)
Table 18. Ranking of Global Top Recombinant Non-Glycosylated Proteins Biosimilars Companies by Revenue (US$ Million) in 2021
Table 19. Global 5 Largest Players Market Share by Recombinant Non-Glycosylated Proteins Biosimilars Revenue (CR5 and HHI) & (2017-2022)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Recombinant Non-Glycosylated Proteins Biosimilars Product Solution and Service
Table 22. Date of Enter into Recombinant Non-Glycosylated Proteins Biosimilars Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2017-2022) & (US$ Million)
Table 25. Global Recombinant Non-Glycosylated Proteins Biosimilars Revenue Market Share by Type (2017-2022)
Table 26. Global Recombinant Non-Glycosylated Proteins Biosimilars Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 27. Global Recombinant Non-Glycosylated Proteins Biosimilars Revenue Market Share by Type (2023-2028)
Table 28. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2017-2022) & (US$ Million)
Table 29. Global Recombinant Non-Glycosylated Proteins Biosimilars Revenue Market Share by Application (2017-2022)
Table 30. Global Recombinant Non-Glycosylated Proteins Biosimilars Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 31. Global Recombinant Non-Glycosylated Proteins Biosimilars Revenue Market Share by Application (2023-2028)
Table 32. North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2017-2022) & (US$ Million)
Table 33. North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2023-2028) & (US$ Million)
Table 34. Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2017-2022) & (US$ Million)
Table 35. Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2023-2028) & (US$ Million)
Table 36. Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Region (2017-2022) & (US$ Million)
Table 37. Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Region (2023-2028) & (US$ Million)
Table 38. Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2017-2022) & (US$ Million)
Table 39. Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2023-2028) & (US$ Million)
Table 40. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2017-2022) & (US$ Million)
Table 41. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2023-2028) & (US$ Million)
Table 42. Sandoz Company Detail
Table 43. Sandoz Business Overview
Table 44. Sandoz Recombinant Non-Glycosylated Proteins Biosimilars Product
Table 45. Sandoz Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022) & (US$ Million)
Table 46. Sandoz Recent Development
Table 47. Pfizer Company Detail
Table 48. Pfizer Business Overview
Table 49. Pfizer Recombinant Non-Glycosylated Proteins Biosimilars Product
Table 50. Pfizer Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022) & (US$ Million)
Table 51. Pfizer Recent Development
Table 52. Teva Pahrmaceutical Company Detail
Table 53. Teva Pahrmaceutical Business Overview
Table 54. Teva Pahrmaceutical Recombinant Non-Glycosylated Proteins Biosimilars Product
Table 55. Teva Pahrmaceutical Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022) & (US$ Million)
Table 56. Teva Pahrmaceutical Recent Development
Table 57. Celltrion Company Detail
Table 58. Celltrion Business Overview
Table 59. Celltrion Recombinant Non-Glycosylated Proteins Biosimilars Product
Table 60. Celltrion Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022) & (US$ Million)
Table 61. Celltrion Recent Development
Table 62. Biocon Company Detail
Table 63. Biocon Business Overview
Table 64. Biocon Recombinant Non-Glycosylated Proteins Biosimilars Product
Table 65. Biocon Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022) & (US$ Million)
Table 66. Biocon Recent Development
Table 67. Amgen Company Detail
Table 68. Amgen Business Overview
Table 69. Amgen Recombinant Non-Glycosylated Proteins Biosimilars Product
Table 70. Amgen Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022) & (US$ Million)
Table 71. Amgen Recent Development
Table 72. Samsung Biologics Company Detail
Table 73. Samsung Biologics Business Overview
Table 74. Samsung Biologics Recombinant Non-Glycosylated Proteins Biosimilars Product
Table 75. Samsung Biologics Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022) & (US$ Million)
Table 76. Samsung Biologics Recent Development
Table 77. Mylan Company Detail
Table 78. Mylan Business Overview
Table 79. Mylan Recombinant Non-Glycosylated Proteins Biosimilars Product
Table 80. Mylan Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022) & (US$ Million)
Table 81. Mylan Recent Development
Table 82. Dr. Reddy's Laboratories Company Detail
Table 83. Dr. Reddy's Laboratories Business Overview
Table 84. Dr. Reddy's Laboratories Recombinant Non-Glycosylated Proteins Biosimilars Product
Table 85. Dr. Reddy's Laboratories Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022) & (US$ Million)
Table 86. Dr. Reddy's Laboratories Recent Development
Table 87. Stada Arzneimittel AG Company Detail
Table 88. Stada Arzneimittel AG Business Overview
Table 89. Stada Arzneimittel AG Recombinant Non-Glycosylated Proteins Biosimilars Product
Table 90. Stada Arzneimittel AG Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022) & (US$ Million)
Table 91. Stada Arzneimittel AG Recent Development
Table 92. Research Programs/Design for This Report
Table 93. Key Data Information from Secondary Sources
Table 94. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Type: 2021 VS 2028
Figure 2. Insulin Features
Figure 3. rHGH Features
Figure 4. Interferon Features
Figure 5. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Application in 2021 & 2028
Figure 6. Oncology Case Studies
Figure 7. Chronic Diseases Case Studies
Figure 8. Autoimmune Diseases Case Studies
Figure 9. Blood Disorders Case Studies
Figure 10. Growth Hormone Deficiency Case Studies
Figure 11. Infectious Diseases Case Studies
Figure 12. Other Diseases Case Studies
Figure 13. Recombinant Non-Glycosylated Proteins Biosimilars Report Years Considered
Figure 14. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 15. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 16. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Region: 2021 VS 2028
Figure 17. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Players in 2021
Figure 18. Global Top Recombinant Non-Glycosylated Proteins Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Non-Glycosylated Proteins Biosimilars as of 2021)
Figure 19. The Top 10 and 5 Players Market Share by Recombinant Non-Glycosylated Proteins Biosimilars Revenue in 2021
Figure 20. North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. North America Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Country (2017-2028)
Figure 22. United States Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Canada Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Country (2017-2028)
Figure 26. Germany Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. France Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. U.K. Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Italy Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Russia Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Nordic Countries Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Region (2017-2028)
Figure 34. China Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Japan Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. South Korea Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Southeast Asia Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. India Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Australia Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Country (2017-2028)
Figure 42. Mexico Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Brazil Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Country (2017-2028)
Figure 46. Turkey Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Saudi Arabia Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Sandoz Revenue Growth Rate in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022)
Figure 49. Pfizer Revenue Growth Rate in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022)
Figure 50. Teva Pahrmaceutical Revenue Growth Rate in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022)
Figure 51. Celltrion Revenue Growth Rate in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022)
Figure 52. Biocon Revenue Growth Rate in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022)
Figure 53. Amgen Revenue Growth Rate in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022)
Figure 54. Samsung Biologics Revenue Growth Rate in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022)
Figure 55. Mylan Revenue Growth Rate in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022)
Figure 56. Dr. Reddy's Laboratories Revenue Growth Rate in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022)
Figure 57. Stada Arzneimittel AG Revenue Growth Rate in Recombinant Non-Glycosylated Proteins Biosimilars Business (2017-2022)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Industry Market Size
